The following table summarizes our stock option activity for the three months ended June 30, 2026:


	Options (in thousands)	Weighted- Average Exercise Prices		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in millions)
Outstanding as of March 31, 2026	3	$	57.19

Granted	—	202.09
Exercised	—	187.57
Forfeited, cancelled or expired	—	59.78
Outstanding as of June 30, 2026	3	$	57.05	1.90	$	0.4
Vested and expected to vest	3	$	57.05	1.90	$	0.4
Exercisable as of June 30, 2026	3	$	57.05	1.90	$	0.4

The following table summarizes our restricted stock units activity for the three months ended June 30, 2026:


	Restricted Stock Units (in thousands)	Weighted- Average Grant Date Fair Values
Outstanding as of March 31, 2026	6,441	$	145.62

Granted	2,864	203.09
Vested	(2,179)	141.93
Forfeited or cancelled	(141)	152.11
Outstanding as of June 30, 2026	6,985	$	170.20

The following table summarizes our performance-based restricted stock unit activity, presented with the maximum number of shares that could potentially vest, for the three months ended June 30, 2026:


	Performance- Based Restricted Stock Units (in thousands)	Weighted- Average Grant Date Fair Value
Outstanding as of March 31, 2026	1,058	$	141.72
Granted	495	203.12
Vested	(385)	146.53
Forfeited or cancelled	(393)	145.90
Outstanding as of June 30, 2026	775	$	176.45

The following table summarizes our market-based restricted stock unit activity, presented with the maximum number of shares that could potentially vest, for the three months ended June 30, 2026:


	Market-Based Restricted Stock Units (in thousands)	Weighted- Average Grant Date Fair Value
Outstanding as of March 31, 2026	890	$	103.80
Granted	—	—
Vested	(96)	152.92
Forfeited or cancelled	(47)	152.92
Outstanding as of June 30, 2026	747	$	94.43

The following table summarizes stock-based compensation expense resulting from stock options, restricted stock units, market-based restricted stock units, performance-based restricted stock units, and the ESPP purchase rights included in our Condensed Consolidated Statements of Operations (in millions):


	Three Months Ended June 30
	2026		2025
Cost of revenue	$	3	$	3
Research and development	106		110
Marketing and sales	14		12
General and administrative	30		27
Stock-based compensation expense	$	153	$	152